Trading Guide: Akums Drugs among 4 top stock ideas for upcoming session
Domestic equities ended lower amid weak global cues, as investors turned cautious ahead of a key US inflation print likely to influence the Fed’s policy trajectory. Early gains were reversed due to profit booking, while subdued oil prices, despite fresh geopolitical developments, offered limited support. FMCG stocks outperformed on expectations of price hikes, and private banks advanced following the RBI's easing of FCNR(B) and ECB norms, whereas metals lagged due to softer commodity prices.
Here are two stocks to buy on Wednesday
Akums Drugs - Buy | CMP: Rs 570 | Stop-loss: Rs 545 | Target: Rs 625-660
Akums Drugs has witnessed a strong breakout above the crucial Rs 550–560 resistance zone, supported by a significant rise in volumes, indicating renewed buying interest. The stock is trading comfortably above its 20, 50, 100, and 200-day EMAs, reinforcing the strength of the ongoing uptrend. RSI has surged above 70, reflecting strong momentum, though minor profit booking cannot be ruled out after the sharp move.
Kunal Kamble, Sr Technical Research Analyst, at Bonanza Portfolio
ABSL AMC - Buy | CMP: Rs 1110 | Stop-loss: Rs 1040 | Target: Rs 1170-1220
Aditya Birla Sun Life AMC has delivered a decisive breakout above the key Rs 1,070–1,080 resistance zone, supported by a sharp increase in volumes, signalling renewed buying interest. The stock is trading above all major moving averages, with the 20-DMA providing immediate support and confirming a strong bullish trend. RSI has moved above 60 and is rising, indicating strengthening momentum without entering overbought territory. The breakout from a multi-week consolidation suggests the potential for further upside.
Kunal Kamble, Sr Technical Research Analyst, at Bonanza Portfolio
HSCL - Buy | CMP: 694 | Stop loss: 740 | Target: 800
Himadri Speciality Chemical is India's only integrated coal-tar chemistry player with a pivot underway into high-value EV materials, anode material, LFP cathode, and specialty carbon black. FY26 delivered PAT of Rs 751 crore (+35% YoY) on revenues of Rs 4,661 crore, while EBITDA crossed Rs 1,000 crore for the first time. The upcoming anthraquinone and carbazole facility will reduce India's import dependence in dyes and pigments, opening a fresh revenue vertical.
Himanshu Gupta, Head of Research - Retail Broking, Jainam
RateGain: Buy | CMP: 786 | Stop loss: Rs 730 | Target: Rs 860
RateGain staged a powerful V-shaped recovery from its Jan lows is now trading at Rs 782, well above both its 50-DMA (Rs 720) and 200-DMA (Rs 630). The weekly chart shows a clear sequence of higher highs and higher lows since Feb 2026, confirming a Stage 2 uptrend. The stock has decisively broken above a multi-month descending channel resistance near Rs 740, with the breakdown-to-breakout structure signaling a change of character.
Himanshu Gupta, Head of Research - Retail Broking, Jainam
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Akums Drugs - Buy | CMP: Rs 570 | Stop-loss: Rs 545 | Target: Rs 625-660
Akums Drugs has witnessed a strong breakout above the crucial Rs 550–560 resistance zone, supported by a significant rise in volumes, indicating renewed buying interest. The stock is trading comfortably above its 20, 50, 100, and 200-day EMAs, reinforcing the strength of the ongoing uptrend. RSI has surged above 70, reflecting strong momentum, though minor profit booking cannot be ruled out after the sharp move.
Kunal Kamble, Sr Technical Research Analyst, at Bonanza Portfolio
ABSL AMC - Buy | CMP: Rs 1110 | Stop-loss: Rs 1040 | Target: Rs 1170-1220
Aditya Birla Sun Life AMC has delivered a decisive breakout above the key Rs 1,070–1,080 resistance zone, supported by a sharp increase in volumes, signalling renewed buying interest. The stock is trading above all major moving averages, with the 20-DMA providing immediate support and confirming a strong bullish trend. RSI has moved above 60 and is rising, indicating strengthening momentum without entering overbought territory. The breakout from a multi-week consolidation suggests the potential for further upside.
Kunal Kamble, Sr Technical Research Analyst, at Bonanza Portfolio
HSCL - Buy | CMP: 694 | Stop loss: 740 | Target: 800
Himadri Speciality Chemical is India's only integrated coal-tar chemistry player with a pivot underway into high-value EV materials, anode material, LFP cathode, and specialty carbon black. FY26 delivered PAT of Rs 751 crore (+35% YoY) on revenues of Rs 4,661 crore, while EBITDA crossed Rs 1,000 crore for the first time. The upcoming anthraquinone and carbazole facility will reduce India's import dependence in dyes and pigments, opening a fresh revenue vertical.
Himanshu Gupta, Head of Research - Retail Broking, Jainam
RateGain: Buy | CMP: 786 | Stop loss: Rs 730 | Target: Rs 860
RateGain staged a powerful V-shaped recovery from its Jan lows is now trading at Rs 782, well above both its 50-DMA (Rs 720) and 200-DMA (Rs 630). The weekly chart shows a clear sequence of higher highs and higher lows since Feb 2026, confirming a Stage 2 uptrend. The stock has decisively broken above a multi-month descending channel resistance near Rs 740, with the breakdown-to-breakout structure signaling a change of character.
Himanshu Gupta, Head of Research - Retail Broking, Jainam
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Next Story